BPGbio appoints Kenin Spivak to Board of Directors

BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors, as an independent director.

“We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott, Executive Chairman of BPGbio. “Kenin’s wealth of experience in multi-disciplinary business fields and expertise in corporate governance are invaluable assets to BPGbio as we as grow our business to the next level by advancing our late-stage therapeutic pipeline and strategic partnerships.”

Mr. Spivak is the founder, chairman and CEO of SMI Group LLC and chairman of its operating units. Prior to SMI Group, Mr. Spivak led multi-national companies with billions of dollars of worldwide sales and operations in more than 30 countries, including serving as CEO of a News Corporation affiliate, a wireless technology company, and distribution companies, principal operating officer of major studio MGM/UA, founding chairman of the Paul Mitchell cosmetology schools, and an officer and director of Merrill Lynch media and entertainment partnerships. He has served as a director of, and advisor to, several healthcare and technology companies.

“BPGbio is greatly accelerating the development of new therapeutics and diagnostics by uniting its pioneering scientific team, the nation’s leading biobank, and cutting-edge AI capabilities,” said Mr. Spivak, adding, “I am honored to join the board and look forward to supporting BPG’s development and commercialization of its late-stage assets.”

Mr. Spivak received A.B., M.B.A. and J.D. degrees from Columbia University, each with honors, completing all three degrees in six years. He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).

BPGbio’s therapeutic pipeline, developed from the company’s NAi Interrogative Biology® Platform, includes therapeutic candidates being studied for glioblastoma multiforme (GBM) in active phase 2b, pancreatic cancer in phase 2a, epidermolysis bullosa (EB), squamous cell carcinoma (SCC), sarcopenia, solid and liquid tumors, Huntington’s disease, Parkinson’s disease, and diabetes type II. The company’s diagnostic pipeline includes its prostate diagnostic panel pstateDx, as well as tests being developed and validated for the detection of Parkinson’s disease, pancreatic cancer, breast cancer and liver disease.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

Zest AI Honored in Fast Company’s 2021 Next Big Things

PR Newswire

Ed Cardon Joins C3 AI as Chair of Federal Systems

Business Wire

Lyssn AI announces a new 5-year contract with State of Utah DHS

Business Wire